Literature DB >> 2842663

Structure/function analysis of ras using random mutagenesis coupled with functional screening assays.

L A Feig1, M Corbley, B T Pan, T M Roberts, G M Cooper.   

Abstract

We review the use of functional assays for the ras protein, p21, that have allowed us to screen for mutant ras genes encoding proteins defective in either interactions with guanine nucleotides or transforming activity. GTP binding and GTP-dependent autokinase activities were assayed directly on lysed bacterial colonies expressing p21. Mutants encoding ras proteins deficient in these activities were isolated after randomly mutagenizing a v-rasH expression vector. Transformation defective mutants were isolated by randomly mutagenizing a v-rasH retroviral shuttle vector. NIH cells were then infected with a stock of nonreplicating mutagenized retroviruses and nontransformed infected colonies were isolated. The mutant ras genes were then rescued from these cells for analysis. Characterization of these mutants defines domains of p21 involved in both biochemical and biological activities and addresses the role of guanine nucleotide binding in p21 function.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2842663     DOI: 10.1210/mend-1-2-127

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  3 in total

1.  Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins.

Authors:  L A Feig; G M Cooper
Journal:  Mol Cell Biol       Date:  1988-06       Impact factor: 4.272

2.  Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP.

Authors:  L A Feig; G M Cooper
Journal:  Mol Cell Biol       Date:  1988-08       Impact factor: 4.272

3.  MAPK/ERK-dependent translation factor hyperactivation and dysregulated laminin γ2 expression in oral dysplasia and squamous cell carcinoma.

Authors:  Martin Degen; Easwar Natarajan; Patricia Barron; Hans R Widlund; James G Rheinwald
Journal:  Am J Pathol       Date:  2012-04-28       Impact factor: 4.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.